论文部分内容阅读
目的:探讨曲美他嗪治疗缺血性心肌病心力衰竭的疗效。方法:选取我院2009年2月-2012年2月收治的84例缺血性心肌病心力衰竭患者,其中,男性44例,年龄在53-85岁之间;女性40例,年龄在55-91岁之间。所有患者均经临床诊断为缺血性心肌病心力衰竭。将84例患者随机分为两组,观察组45例,对照组39例。首先对所有患者进行常规基础治疗,观察组在常规治疗的基础上采用曲美他嗪治疗,对照组仅采用常规基础治疗。对两组的治疗情况进行跟踪观察,并记录所得数据。结果:经治疗,两组患者的病情均有一定程度的改善。84例患者中,观察组45例,显效23例,有效15例,无效7例,有效率为84.4%;对照组39例,显效18例,有效11例,无效10例,有效率为74.4%。结论:曲美他嗪治疗缺血性心肌病心力衰竭,效果较为显著,值得临床推广应用。
Objective: To investigate the efficacy of trimetazidine in the treatment of heart failure of ischemic cardiomyopathy. Methods: Eighty-four patients with heart failure of ischemic cardiomyopathy were enrolled in our hospital from February 2009 to February 2012. Among them, 44 were males, ranging in age from 53 to 85 years; 40 were females, aged 55- 91 years old. All patients were clinically diagnosed as ischemic cardiomyopathy heart failure. 84 patients were randomly divided into two groups, observation group 45 cases, control group 39 cases. All patients were treated with routine basic treatment. The observation group was treated with trimetazidine on the basis of routine treatment, while the control group was treated with routine basic treatment. Follow up the treatment of both groups and record the data. Results: After treatment, the two groups of patients have a certain degree of improvement. Of 84 patients, the observation group of 45 cases, effective in 23 cases, effective in 15 cases, ineffective in 7 cases, the effective rate was 84.4%; control group of 39 cases, 18 cases markedly effective in 11 cases, ineffective in 10 cases, the effective rate was 74.4% . Conclusion: Trimetazidine treatment of ischemic cardiomyopathy heart failure, the effect is more significant, worthy of clinical application.